Single-group, Phase I study (n=12) assessing two oral psilocybin doses (25 mg; second dose 25 or 50 mg) with behavioural support for adults with methamphetamine use disorder.
This single-group Phase I study evaluates the safety and feasibility of two oral psilocybin sessions given approximately 4 weeks apart, each delivered with trained facilitators and an overnight clinical observation period.
Participants receive preparatory psychological support (≥6 hours), an 8-hour dosing observation and overnight stay, and integration sessions; follow-up continues to approximately 26 weeks to assess safety and feasibility.
Psilocybin administered in capsules with psychological support; two doses ~4 weeks apart.
Second dose 25 mg or 50 mg (per protocol)